Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 plus palbociclib ± fulvestrant in HER2-positive metastatic breast cancer
CTR20210592Phase 2Terminated
- Sponsor
- Alphamab Oncology
- Start
- Dec 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab in breast cancer, sponsored by Alphamab Oncology. Started Dec 2021; status: terminated.
02
Drugs
anbenitamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20210592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210592.